Design and synthesis of potent, non-peptidic inhibitors of HPTPbeta.
The sulfamic acid phosphotyrosine mimetic was coupled with a previously known malonate template to obtain highly selective and potent inhibitors of HPTPbeta. Potentially hydrolyzable malonate ester functionalities were replaced with 1,2,4-oxadiazoles without a significant effect on HPTPbeta potency.
Amarasinghe
Kande K D
KK
Procter & Gamble Pharmaceuticals, Health Care Research Center, Mason, OH 45040, USA. Amarasinghe.kk@pg.com
Evdokimov
Artem G
AG
Evidokimov
Artem G
AG
Xu
Kevin
K
Clark
Cynthia M
CM
Maier
Matthew B
MB
Srivastava
Anil
A
Colson
Anny-Odile
AO
Gerwe
Gina S
GS
Stake
George E
GE
Howard
Brian W
BW
Pokross
Matthew E
ME
Gray
Jeffrey L
JL
Peters
Kevin G
KG
D002626:Chemistry, Pharmaceutical / Q000379:methods*; D018360:Crystallography, X-Ray; D015195:Drug Design; D006860:Hydrogen Bonding; D006868:Hydrolysis; D008956:Models, Chemical; D008958:Models, Molecular; D015394:Molecular Structure; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors*; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors*; D054633:Receptor-Like Protein Tyrosine Phosphatases, Class 5; D013329:Structure-Activity Relationship
D009419:Nerve Tissue Proteins; D017027:Protein Tyrosine Phosphatases; D054633:Receptor-Like Protein Tyrosine Phosphatases, Class 5